1. Home
  2. ICD-10-PCS
  3. XW023X7
  4. Share
  5. Feedback

ICD 10 Code XW023X7

Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
“Introduce Tixagev/Cilgavim in Muscle, Perc, New Tech 7” for short

XW023X7 is a valid billable ICD-10 procedure code for Introduction of Tixagevimab and Cilgavimab Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7. It is found in the 2025 version of the ICD-10 Procedure Coding System (PCS) and can be used in all HIPAA-covered transactions from Oct 01, 2024 - Sep 30, 2025.

Introduction involves:
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

Percutaneous approach involves:
Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure

Broad Consortium Microbiota-based Live Biotherapeutic Suspension device includes:

  • REBYOTA(R)

ICD-10-PCS code structure for XW023X7 — See Table View

1: Section X New Technology
2: Body System W Anatomical Regions
3: Root Operation 0 Introduction
4: Body Part 2 Muscle
5: Approach 3 Percutaneous
6: Device X Broad Consortium Microbiota-based Live Biotherapeutic Suspension
7: Qualifier 7 New Technology Group 7

See also

  • The ICD-10-PCS Index of common procedure terms.
  • New Technology terms in the ICD-10-PCS Definitions table. These definitions may also provide additional explanation and/or examples within this section.
  • The ICD-10-PCS Device Aggregation Table containing entries that correlate a specific ICD-10-PCS device value with a general device value to be used in tables containing only general device values.